ArticleIET systems biology
Characterising and Evaluating the Immune Microenvironment Landscapes of Colorectal Cancer Shaped by Different Therapies.
Article in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) occurs as the third most common cancer with high mortality across the world. Understanding the intratumoral immune cell heterogeneity and their responses to various therapies is crucial for enhancing patient outcomes. This study aimed to characterise and evaluate the immune microenvironment landscapes of CRC shaped by different therapies including CD73 inhibitor, PD-1 blockade and photothermal therapy (PTT). Our investigation revealed that three therapies could commonly modulate the down-regulation of Treg, M2 macrophage and Ptprj+ G4 granulocyte, up-regulation of effector/memory T cell, M1 macorphage and Hilpda+ G1 granulocyte. Moreover, we identified the uniquely dis-regulated cell types and pathway activities response to each therapy, such as CD73 inhibitor enriched more Cd8+ memory and central memory (CM) cell, PD-1 blockade with more Cd8+ CTL and Cxcl3+ G2 granulocyte, and PTT with more Cd8+ effector memory and Rethlg+ G3 granulocyte cell. These responses disordered the glycolysis, angiogenesis, phagocytosis functions and cellular communication to reshape the CRC tumour immune microenvironment. We provide the detail insights into the intratumoral immunomodulation preferences of CRC mice treated with CD73 inhibitor, PD-1 blockade and PTT therapies, which might contribute to the ongoing development of more effective anticancer strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.